Spike Protein News and Research

RSS

Specific area of SARS-CoV-2 spike protein found to be a promising target for pan-coronavirus vaccine

Researchers at the Francis Crick Institute have shown that a specific area of the SARS-CoV-2 spike protein is a promising target for a pan-coronavirus vaccine that could offer some protection against new virus variants, common colds, and help prepare for future pandemics.

27 Jul 2022

Study finds specific molecular barriers to SARS-CoV-2 replication in bat cells

Bat cells have specific molecular barriers to deal with SARS-CoV-2 replication, according to a study published in Journal of Virology —publication of the American Society of Microbiology— which includes the participation of Jordi Serra-Cobo, lecturer of the Faculty of Biology and the Biodiversity Research Institute (IRBio) of the University of Barcelona and expert on ecoepidemiological studies.

27 Jul 2022

Study shows the emerging Omicron sublineage BA.2.75 does not show greater immune evasion than BA.5

Researchers assessed the sensitivity of SARS-CoV-2 Omicron BA.2.75 variant to neutralizing antibodies.

27 Jul 2022

Temporal changes in CD4 T-lymphocyte dynamics upon immunization against SARS-CoV-2 spike protein

Researchers assessed changes in CD4 T-lymphocyte temporal dynamics by evaluating T-lymphocyte responses to SARS-CoV-2 S using Foxp3-Tocky mice and Nr4a3-Tocky mice.

27 Jul 2022

The neutralizing antibody response in mRNA vaccinated and boosted healthcare workers against major circulating SARS-CoV-2 Omicron subvariants

Researchers assessed the duration of the neutralizing antibody responses after SARS-CoV-2 mRNA booster vaccination.

27 Jul 2022

Study estimates prevalence of SARS-CoV-2 omicron breakthrough infections in South Africa

Scientists have described the prevalence of vaccine breakthrough SARS-CoV-2 infection in South Africa during the period of delta and omicron circulation.

27 Jul 2022

A VSV-based COVID vaccine effective against SARS-CoV-2 variants

A new study discusses the development of recombinant vesicular stomatitis virus COVID-19 vaccines.

25 Jul 2022

Bivalent mRNA vaccine induces powerful antibody response to SARS-CoV-2 Omicron subvariants

Researchers discuss the development and efficacy of a bivalent mRNA vaccine against emerging variants such as BA.2.12.1, BA.4, or BA.5.

25 Jul 2022

Why Omicron is more infectious than other SARS-CoV-2 variants

Researchers describe SARS-CoV-2 Omicron mutations and their impact on neutralization and infectivity.

25 Jul 2022

Scientists explore SARS-CoV-2 spike protein and platelet-activating factor

Researchers assessed the association between platelet-activating factor (PAF) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein.

25 Jul 2022

SARS-CoV-2 spike protein can lead to heart muscle injury through the inflammatory process

Heart damage is common among patients hospitalized with COVID-19, leading many to wonder how the virus affects the heart.

25 Jul 2022

Antibodies' neutralization efficacy against Omicron variants BA.1 And BA.2 wanes rapidly, study finds

The Omicron variant of the SARS-CoV-2 virus was first detected in South Africa in November 2021. The high level of infectiousness of the virus and its ability to quickly spawn additional variants has also been observed in Germany: Since January 2022 the Omicron variant BA.1 has dominated here, followed in subsequent months by the variant BA.2.

22 Jul 2022

Study examines the maintenance of immunity to SARS-CoV-2 after natural infection or post-vaccination

A new study examined the maintenance of memory B cell responses to SARS-CoV-2, the virus that causes COVID-19, after recovery from natural infection or post-vaccination.

22 Jul 2022

IUPUI researchers are developing a fast, efficient COVID-19 biosensor

As the BA.5 omicron variant continues to spread, health experts are increasingly preparing for a future in which such COVID-19 variants emerge, surge and recede similar to seasonal flu.

21 Jul 2022

A different approach to build a more durable, broadly effective COVID-19 vaccine

Researchers at University of California San Diego School of Medicine, with colleagues elsewhere, describe a different way to build a COVID-19 vaccine, one that would, in theory, remain effective against new and emerging variants and could be taken as a pill, by inhalation or other delivery methods.

21 Jul 2022

High-level resistance of SARS-CoV-2 BA.4 against neutralizing antibodies

Researchers evaluates the sensitivity of BA.4 in both vaccinated and unvaccinated individuals infected with the SARS-CoV-2 variants.

20 Jul 2022

How the Omicron variant shifted the biology of SARS-CoV-2

Researchers discuss significant antigenic changes within the spike protein of new SARS-CoV-2 VOCs like the Omicron variant.

20 Jul 2022

The clinical, epidemiological, and evolutionary consequences of a potential SARS-CoV-2-related bat virus spillover into humans

A team of scientists from France has recently described the epidemiological and clinical consequences of a bat sarbecovirus infection in humanized mice.

20 Jul 2022

Novavax COVID-19 vaccine now available in the U.S. to protect against severe disease

The Centers for Disease Control and Prevention (CDC) has recommended that Novavax's COVID-19 vaccine be used as another primary series option for adults in the United States ages 18 years and older.

20 Jul 2022

Neutralizing activity of skin-patch delivered subunit vaccine against SARS-CoV-2 variants

A new study involved an analysis of the serum from a previous study to determine neutralizing activity against new variants.

20 Jul 2022

Spike Protein News and Research

Specific area of SARS-CoV-2 spike protein found to be a promising target for pan-coronavirus vaccine

Study finds specific molecular barriers to SARS-CoV-2 replication in bat cells

Study shows the emerging Omicron sublineage BA.2.75 does not show greater immune evasion than BA.5

Temporal changes in CD4 T-lymphocyte dynamics upon immunization against SARS-CoV-2 spike protein

The neutralizing antibody response in mRNA vaccinated and boosted healthcare workers against major circulating SARS-CoV-2 Omicron subvariants

Study estimates prevalence of SARS-CoV-2 omicron breakthrough infections in South Africa

A VSV-based COVID vaccine effective against SARS-CoV-2 variants

Bivalent mRNA vaccine induces powerful antibody response to SARS-CoV-2 Omicron subvariants

Why Omicron is more infectious than other SARS-CoV-2 variants

Scientists explore SARS-CoV-2 spike protein and platelet-activating factor

SARS-CoV-2 spike protein can lead to heart muscle injury through the inflammatory process

Antibodies' neutralization efficacy against Omicron variants BA.1 And BA.2 wanes rapidly, study finds

Study examines the maintenance of immunity to SARS-CoV-2 after natural infection or post-vaccination

IUPUI researchers are developing a fast, efficient COVID-19 biosensor

A different approach to build a more durable, broadly effective COVID-19 vaccine

High-level resistance of SARS-CoV-2 BA.4 against neutralizing antibodies

How the Omicron variant shifted the biology of SARS-CoV-2

The clinical, epidemiological, and evolutionary consequences of a potential SARS-CoV-2-related bat virus spillover into humans

Novavax COVID-19 vaccine now available in the U.S. to protect against severe disease

Neutralizing activity of skin-patch delivered subunit vaccine against SARS-CoV-2 variants

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News